Membership Directory
Acambis, Inc.
Category: Drug Development
Phone: (617) 761-4200
Fax: (617) 494-1741
Website: http://www.acambis.com
About Acambis
Acambis is a leading vaccine company developing novel vaccines that address significant unmet medical needs or substantially improve standards of care. ChimeriVax™-JE, Acambis’ most advanced product in its development-stage pipeline, has to date shown an excellent safety and efficacy profile following pivotal Phase 3 trials. Acambis’ proprietary ChimeriVax™ technology, developed in association with St Louis University, has also been used to develop ChimeriVax™-West Nile, which is undergoing Phase 2 clinical testing, making it the most advanced investigational vaccine against the West Nile virus. Acambis has established a global collaboration with sanofi pasteur for further development and commercialisation of the vaccine. ChimeriVax™ has also been applied to development of sanofi pasteur’s tetravalent dengue vaccine, which has successfully demonstrated proof-of-concept in a Phase 2 trial by generating 100% seroconversion to all four dengue virus serotypes.
Acambis also has the only vaccine in development against Clostridium difficile bacteria, a leading cause of hospital-acquired infections. C. difficile is estimated to cause at least 360,000 cases of C. difficile-associated disease in the US alone with annual costs to the healthcare system of $3.2bn. Acambis’ influenza programme aims to develop a universal vaccine against influenza, for which a universal ‘A’ strain vaccine, ACAM-FLU-A, was recently tested in a Phase 1 trial. Acambis is currently undertaking pre-clinical testing of a vaccine candidate, dl5-29, against genital herpes.
Acambis is recognised internationally as the leading producer of smallpox vaccines for emergency-use stockpiles held by the US Government and several other governments around the world. Acambis developed its ACAM2000™ smallpox vaccine under contracts with the US Government.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US, and is listed on the London Stock Exchange (ACM). More information is available at www.acambis.com.
Back to list



PHONE: 617.674.5100
EMAIL: